The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Impairment of dendritic cells (DC), the most effective activators of anticancer immune responses, is one mechanism for defective antitumor immunity, but the causes of DC impairment are incompletely understood. We evaluated the association of impaired DC differentiation with angiogenesis-associated molecules D-dimer, vascular endothelial growth factor (VEGF), urokinase plasminogen activator (uPA), and plasminogen activator inhibitor (PAI-1) in peripheral blood from 41 patients with lung, breast, and colorectal carcinoma. Subsequently, we studied the effect of administration of the anti-VEGF antibody (bevacizumab) on DC maturation and function in vivo. Compared with healthy volunteers, cancer patients had a bias toward the immunoregulatory DC2, had deficits in DC maturation after overnight in vitro culture, and had a significant increase in immature myeloid cell progenitors of DC (0.50 +/- 0.31% vs. 0.32 +/- 0.16% of peripheral blood mononuclear cells, respectively, P = 0.011). A positive correlation was found between the percentage of DC2 and PAI-1 (R = 0.50) and between immature myeloid cells and VEGF (R = 0.52). Bevacizumab administration to cancer patients was associated with a decrease in the accumulation of immature progenitor cells (0.39 +/- 0.30% vs. 0.27 +/- 0.24%, P = 0.012) and induced a modest increase in the DC population in peripheral blood (0.47 +/- 0.23% vs. 0.53 +/- 0.30%). Moreover, anti-VEGF antibody treatment enhanced allo-stimulatory capacity of DC and T cell proliferation against recall antigens. These data suggest that DC differentiation is negatively associated with VEGF levels and may be one explanation for impaired anticancer immunity, especially in patients with advanced malignancies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“improved DC maturation”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Osada et al., 2008
Citations
Cites
Peichev, M., Naiyer, A. J., Pereira, D., Zhu, Z., Lane, W. J., Williams, M., Oz, M. C., Hicklin, D. J., Witte, L., Moore, M. A. S., et al. (2000) · Blood · doi:10.1182/blood.v95.3.952.003k27_952_958 · Cited by 2,277 · cited 1×
“CECs were deWned as CD45¡/Flk+/CD15¡ and CEPs as CD45¡/Flk+/CD133+ [21, 22].”
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977 · cited 3×
“Furthermore, high VEGF levels appear to block DC diVerentiation from immature precursors [16].”
Dhodapkar, M. V., Steinman, R. M., Krasovsky, J., Munz, C., & Bhardwaj, N. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.2.233 · Cited by 1,359 · cited 1×
“One mechanism for doing so is the inhibition of DC function [ 5 ].”
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337 · cited 2×
“Because Gabrilovich and colleagues [10, 11] showed that the undiVerentiated hematopoietic cells from cancer patients inhibited the function of fully diVerentiated DC, we hypothesized that administration of anti-VEGF Ab”
Gabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S., & Carbone, D. P. (1998) · Blood · doi:10.1182/blood.v92.11.4150 · Cited by 1,048 · cited 1×
“studies performed by Gabrilovich, Carbone, and colleagues [10, 28, 29], the presence of increased iMC in cancer patients, which is associated with elevated levels of VEGF, was demonstrated to be involved in mediating DC dysfunction.”
Regulation of angiogenesis via vascular endothelial growth factor receptors.
Veikkola, T., Karkkainen, M. J., Claesson, L., & Alitalo, K. K. (2000) · PubMed · Cited by 864
SERAFINI, P., BORRELLO, I., & BRONTE, V (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.07.005 · Cited by 762
Clinical significance of defective dendritic cell differentiation in cancer.
Almand, B., Resser, J. R., Lindman, B. R., Nadaf, S., Clark, J. I., Kwon, E. D., Carbone, D. P., & Gabrilovich, D. I. (2000) · PubMed · Cited by 699
Look, M. P., van Putten, W. L. J., Duffy, M. J., Harbeck, N., Christensen, I. J., Thomssen, C., Kates, R., Spyratos, F., Ferno, M., Eppenberger-Castori, S., et al. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.2.116 · Cited by 596 · cited 1×
“Since PAI-1 is associated with poor prognosis of patients with diVerent types of cancers [24, 25, 30], PAI-1 may have indirect correlation with immunoregulatory DC (DC2).”
The multifaceted circulating endothelial cell in cancer: towards marker and target identification
Bertolini, F., Shaked, Y., Mancuso, P., & Kerbel, R. S. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1971 · Cited by 575 · cited 1×
“CECs were deWned as CD45¡/Flk+/CD15¡ and CEPs as CD45¡/Flk+/CD133+ [21, 22].”
Cited by
Items 101–200 of 324
Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge
Marmorino, F., Boccaccino, A., Germani, M. M., Falcone, A., & Cremolini, C. (2020) · Cancers · doi:10.3390/cancers12082317 · Cited by 56
Mulligan, J. K., Day, T. A., Gillespie, M. B., Rosenzweig, S. A., & Young, M. R. I. (2009) · Human Immunology · doi:10.1016/j.humimm.2009.01.014 · Cited by 56
The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients
Tobin, R. P., Davis, D. M., Jordan, K. R., & McCarter, M. D. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5vmr1016-449r · Cited by 57
“Bevacizumab Colon and several other cancers Angiogenesis inhibitor Inhibits angiogenesis by inhibiting VEGF binding to VEGFR Decreases circulating total and KIT MDSC frequency ↑PFS; ↑OS (cervical and colon cancer) [42, 43]”
BackgroundVascular endothelial growth factor and programmed death‐1 pathway inhibitors in renal cell carcinoma
Mantia, C. M., & McDermott, D. F. (2019) · Cancer · doi:10.1002/cncr.32361 · Cited by 59
Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment
Arina, A., Corrales, L. P., & Bronte, V. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.01.002 · Cited by 56
Han, Z., Dong, Y., Lu, J., Yang, F., Zheng, Y., & Yang, H. (2021) · American Journal of Cancer Research · Cited by 65
Bridging angiogenesis and immune evasion in the hypoxic tumor microenvironment
Schito, L. (2018) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00209.2018 · Cited by 52
“Likewise, cancer-associated DCs upregulate PD-L1 in response to tumor-derived VEGF (35); on the other hand, the FDA-approved VEGF neutralizing antibody bevacizumab decreases circulating immature DCs when administered to patients bearing breast, colorectal, and lung carcinomas, thus potentiating oncolytic immune respon…”
BackgroundHypoxia: Turning vessels into vassals of cancer immunotolerance
Schito, L., & Rey, S. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.015 · Cited by 49
“to patients with colorectal, breast, and lung carcinomas whilst enhancing anti-tumoral immunity [40].”
BackgroundLee, D. Y., Im, E., Yoon, D., Lee, Y., Kim, G., Kim, D., & Kim, S.-H. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.001 · Cited by 52
Bellati, F., Napoletano, C., Ruscito, I., Pastore, M., Pernice, M., Antonilli, M., Nuti, M., & Panici, P. B. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9351-4 · Cited by 48
“It has been demonstrated that VEGF interferes with dendritic cells maturation [46] and can induce and/or maintain Tregs in cancer patients [ 47 , 48].”
BackgroundSensitivity of Dendritic Cells to Microenvironment Signals
Motta, J. M., & Rumjanek, V. M. (2016) · Journal of Immunology Research · doi:10.1155/2016/4753607 · Cited by 49
“They were able to show that anti-VEGF treatment increases cell ability of activating and promoting lymphocyte proliferation [53].”
How regional analgesia might reduce postoperative cancer recurrence
Cata, J. P., Gottumukkala, V. N. R., & Sessler, D. I. (2011) · European Journal of Pain Supplements · doi:10.1016/j.eujps.2011.08.017 · Cited by 52
The Therapeutic Potential of Tackling Tumor-Induced Dendritic Cell Dysfunction in Colorectal Cancer
Subtil, B., Cambi, A., Tauriello, D. V. F., & de Vries, I. J. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.724883 · Cited by 50
Zeng, W., Liu, H., Mao, Y., Jiang, S., Hao, Y., Zhang, Z., Wang, M., & Zong, Z. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5673 · Cited by 49
“In addition, the admin‑ istration of bevacizumab (anti‑VEGF) therapy to patients with CRC results in a decrease in the concentration of immature progenitor cells, with a moderate increase in the number of DCs in the peripheral blood (161).”
BackgroundControl of the Adaptive Immune Response by Tumor Vasculature
Mauge, L., Terme, M., Tartour, É., & Helley, D. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00061 · Cited by 49
“This treatment can also promote the differentiation of DCs with a parallel decrease of the immature myeloid cell population in different tumors (104).”
BackgroundImmune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review
Attili, I., Passaro, A., Corvaja, C., Aliaga, P. T., Signore, E. D., Spitaleri, G., & de Marinis, F. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102602 · Cited by 47
Zhou, C., Dong, X., Chen, G., Wang, Z., Wu, X., Yu, Y., Zhang, Y., Cheng, Y., Pan, H., Zhang, X., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03658-y · Cited by 47
Improving lung cancer survival; time to move on
Heuvers, M. E., Hegmans, J. P., Stricker, B. H. C., & Aerts, J. G. J. V. (2012) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-12-77 · Cited by 45
“survival of lung cancer [31,32].”
Luengas‐Martinez, A., Hardman, J. A., Paus, R., & Young, H. S. (2020) · Experimental Dermatology · doi:10.1111/exd.14151 · Cited by 47
Anti–Vascular Endothelial Growth Factor Therapy in Breast Cancer: Game Over?
Sledge, G. W. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.1298 · Cited by 46
The role of dendritic cells in cancer immunity and therapeutic strategies
Tai, Y., Chen, M., Wang, F., Fan, Y., Zhang, J., Cai, B., Lin, Y., Luo, Y., & Li, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111548 · Cited by 45
Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer
Thomas, J. V., Leal, A. D., & Overman, M. J. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.02.002 · Cited by 45
Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma
Lü, L., Saha, D., Martuza, R. L., Rabkin, S. D., & Wakimoto, H. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1612-1 · Cited by 43
Slingluff, C. L., Petroni, G. R., Molhoek, K. R., Brautigan, D. L., Chianese‐Bullock, K. A., Shada, A. L., Smolkin, M. E., Olson, W. C., Gaucher, A., Chase, C. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3919 · Cited by 45
“Also VEGF blockade can improve T cell immunity and dendritic cell function [20-23].”
BackgroundCho, D. C., Puzanov, I. J., Regan, M. M., Schwarzberg, T., Seery, V. J., Lee, M.-Y., Liu, V. Y., Bhatt, R. S., Koon, H. B., Mier, J. W., et al. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181952b1d · Cited by 43
“Total 19 (14-22) 15 (12-20) 20 (17-25) Total percentage (of 28 doses) 68% (50%-79%) 54% (43-54%) 71% (59%-80%) Patients not receiving any doses week 2 6 (26) 95% CI (10-48) 6 (40) 95% CI (16-68) 0 (0) 95% CI (0-37) Patients proceeding to cycle 2 1 (4) 1 (7) 0 (0) Response Stable disease 3 (13) 3 (20) 0 (0) Progressive…”
BackgroundPhase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma
Jonasch, E. W., Stadler, W. M., Bukowski, R. M., Hayes, T. G., Varadhachary, A., Malik, R. K., Figlin, R. A., & Srinivas, S. (2008) · Cancer · doi:10.1002/cncr.23519 · Cited by 43
Autologous stromal vascular fraction cells: A tool for facilitating tolerance in rheumatic disease
Ichim, T. E., Harman, R. J., Min, W., Minev, B., Solano, F., Rodríguez, J. P., Alexandrescu, D. T., de Necochea-Campion, R., Hu, X., Marleau, A. M., et al. (2010) · Cellular Immunology · doi:10.1016/j.cellimm.2010.04.002 · Cited by 45
“tumors was demonstrated to increase DC maturation and restore T cell activating activity [46].”
BackgroundTumor rim cells: From resistance to vascular targeting agents to complete tumor ablation
Seidi, K., Jahanban-Esfahlan, R., & Zarghami, N. (2017) · Tumor Biology · doi:10.1177/1010428317691001 · Cited by 41
The role of myeloid‐derived suppressor cells in gastrointestinal cancer
Cui, C., Lan, P., & Fu, L. (2021) · 癌症:英文版 · doi:10.1002/cac2.12156 · Cited by 42
Merhi, M., Ahmad, F., Taib, N., Inchakalody, V. P., Shahab Uddin, M. S., Shablak, A., & Dermime, S. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.01.001 · Cited by 42
“Other therapies including cetuximab (anti-EGFR) [324] and bevacizumab (anti-VEGF) [325,326] might also promote the activity of the immune system and synergize the effect of ICIs.”
The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy
Wolf, K. D., Vermaelen, K., Meerleer, G. D., Lambrecht, B. N., & Ost, P. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1042198 · Cited by 41
“STAT3 signaling and stimulates the antigen presenting capacity of DCs which results in increased T cell proliferation.(114) Therefore, combination of radiotherapy with bevacizumab might promote the formation of a radiationinduced antitumor immune response in patients with RCC.”
Khaled, N. B., Seidensticker, M., Ricke, J., Mayerle, J. V., Oehrle, B., Rössler, D. C., Teupser, D., Ehmer, U., Bitzer, M., Waldschmidt, D., et al. (2022) · Future Oncology · doi:10.2217/fon-2021-1261 · Cited by 40
Tumor Vasculature as an Emerging Pharmacological Target to Promote Anti-Tumor Immunity
Tzeng, H., & Huang, Y.-J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054422 · Cited by 38
“Bevacizumab, a monoclonal antibody against VEGF as a cancer treatment, increases the dendritic cell (DC) population, improving their T cell stimulatory capacity [130].”
BackgroundRegulatory T cells as suppressors of anti-tumor immunity: Role of metabolism
Rosa, V. D., Rella, F. D., Giacomo, A. D., & Matarese, G. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.04.001 · Cited by 39
Regulation of tumor angiogenesis by the crosstalk between innate immunity and endothelial cells
Ebeling, S., Kowalczyk, A., Pérez-Vázquez, D., & Mattiola, I. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1171794 · Cited by 39
Amin, A., & Hammers, H. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03120 · Cited by 38
“Bevacizumab has been noted to promote activity and reverse the inhibitory effects of VEGF on dendritic cells (34, 35).”
BackgroundSumransub, N., Vantanasiri, K., Prakash, A., & Lou, E. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.05.001 · Cited by 38
“Immunogenic cell death induced by chemotherapy leads to antigen release and immune activation, which could sensitize tumor cells to ICI therapy.96 Multiple studies combine chemotherapy with anti-VEGF, as its inhibition can lead to reversal of myeloid-derived suppressor cell (MDSC), tumor-associated macrophage (TAM), a…”
BackgroundAhluwalia, P. K., Ahluwalia, M., Mondal, A. K., Sahajpal, N., Kota, V. K., Rojiani, M. V., & Kolhe, R. B. (2021) · Cancers · doi:10.3390/cancers13164037 · Cited by 40
“Also, VEGF blockade therapy through anti-VEGF antibody has been shown to stimulate DCs and T cells to enhance tumor immunity [142].”
BackgroundHamid, M. A., Pammer, L. M., Lentner, T., Doleschal, B., Gruber, R., Kocher, F., Gasser, E., Jöbstl, A., Seeber, A., & Amann, A. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01583-w · Cited by 36
“Several studies have shown that antiangiogenic agents, by inhibiting VEGF signaling, normalize tumor vasculature and increase T-cell infiltration, thereby enhancing immune cell activation [43].”
BackgroundVaccination approach to anti-angiogenic treatment of cancer
Wentink, M. Q., Huijbers, E. J. M., de Gruijl, T. D., Verheul, H. M. W., Olsson, A., & Griffioen, A. W. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.01.005 · Cited by 34
“Although the described effects of bevacizumab treatment on DC maturation are inconsistent [95,26,1,31], it seems that bevacizumab as well as sunitinib treatment reduces the number of immature myeloid cells and consequently MDSCs that can arise from them [95,26,61].”
BackgroundTumor-derived factors affecting immune cells
Russo, V. E. A., & Protti, M. P. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.005 · Cited by 36
Immunoregulation mechanism of VEGF signaling pathway inhibitors and its efficacy on the kidney
Li, J., Li, X., & Li, C. (2023) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2023.09.005 · Cited by 33
Shen, M., Du, Y., & Ye, Y. (2021) · Medical Review · doi:10.1515/mr-2021-0014 · Cited by 34
“VEGF inhibition has also been shown to enhance DC maturation in human patients, suggesting that this may contribute to the efficacy of VEGF inhibitors in clinical settings [123].”
BackgroundAl-Ostoot, F. H., Salah, S., & Khanum, S. A. (2024) · Cancer Investigation · doi:10.1080/07357907.2024.2361295 · Cited by 35
“…of the cancer immunity cycle, anti-angiogenic medications may be able to restore the host’s potential anti-immune response. whereby, Inhibiting VEGF with bevacizumab improved the antigen-presenting potential of peripheral blood dendritic cells in a trial of 19 patients with colon cancer (246).”
Aparicio, L. M. A., Fernandez, I. P., & Cassinello, J. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1657-7 · Cited by 33
“ence of immature DCs and immature myeloid cells in peripheral blood [15].”
BackgroundImmunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents
Fucikova, J. P., Palová-Jelínková, L., Klapp, V., Holíček, P., Láníčková, T., Kašíková, L., Drozenová, J., Cibula, D., Álvarez-Abril, B., García-Martínez, E., et al. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.01.010 · Cited by 32
Checkpoint inhibitors and anti-angiogenic agents: a winning combination
Brest, P., Mograbi, B., Pagès, G., Hofman, P. M., & Milano, G. A. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02437-1 · Cited by 33
“VEGF, through the inhibition of NF-κ B; decreases the production of certain in fl am-matory cytokines that play critical roles in both activation/ maturation and migration and numbers of dendritic cells [22, 23].”
BackgroundThe Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies
Xu, M. M., Pu, Y., Zhang, Y., & Fu, Y. (2016) · Trends in Immunology · doi:10.1016/j.it.2015.12.007 · Cited by 33
“Bevacizumab was shown to facilitate DCs maturation and increase DC population in peripheral blood from patients with lung, breast, and colorectal carcinoma [36].”
BackgroundSalter, R. D., & Shurin, M. R. (2009) · Springer eBooks · doi:10.1007/978-0-387-88611-4 · Cited by 34
Sprague, L., Muccioli, M., Pate, M., Meles, E., McGinty, J. W., Nandigam, H., Venkatesh, A., Gu, M.-Y., Mansfield, K., Rutowski, A., et al. (2011) · BMC Immunology · doi:10.1186/1471-2172-12-35 · Cited by 37
“In particular, DCs showing low levels of costimulatory molecules have been detected in tumors expressing high levels of VEGF [65] and tumor patients treated with antiVEGF antibody showed a decrease in the levels of immunosuppressive DCs [66].”
BackgroundNanomedicines modulating myeloid-derived suppressor cells for improving cancer immunotherapy
Dai, X., Ren, L. F., Liu, M., Cai, H., Zhang, H., Gong, Q., Gu, Z., & Luo, K. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101163 · Cited by 30
Brackenier, C., Kinget, L., Cappuyns, S., Verslype, C., Beuselinck, B., & Dekervel, J. (2023) · Cancers · doi:10.3390/cancers15020348 · Cited by 30
MicroRNAs and Tumor Vasculature Normalization: Impact on Anti-Tumor Immune Response
Matejuk, A., Collet, G., Nadim, M., Grillon, C., & Kieda, C. (2013) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-013-0231-4 · Cited by 30
“In some studies VEGF has been shown to inhibit the maturation and function of dendritic cells (Gabrilovich et al. 1996; Osada et al. 2008).”
BackgroundKong, X., Lü, P., Liu, C., Guo, Y., Yang, Y., Peng, Y., Wang, F., Zhang, B., Dou, X., Shi, H., et al. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12001 · Cited by 32
“Bevacizumab confers immunomodulatory effects by inhibiting VEGF and promoting DC maturation (40).”
BackgroundDendritic cells: understanding ontogeny, subsets, functions, and their clinical applications
Li, W., Yu, C., Zhang, X., Gu, Y., He, X., Xu, R., Xu, J. F., Yu, G., & Wu, Y. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00300-8 · Cited by 30
“Murine studies show that VEGF blockade synergizes with peptide-pulsed DCs to amplify antitumor immunity [307, 308], whereas in vitro, VEGF impedes monocyte differentiation into DCs [305, 309].”
Neoangiogenesis in Melanoma: An Issue in Biology and Systemic Treatment
Quaresmini, D., & Guida, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584903 · Cited by 30
“To confirm this role of VEGF, the anti-VEGF antibody Bevacizumab induces DC maturation and a reduction in Tregs andMDSCs recruitment to cancer sites (22, 30, 31).”
BackgroundVEGF: Potential therapy for renal regeneration
Chade, A. (2011) · F1000 Medicine Reports · doi:10.3410/m4-2 · Cited by 29
A cancer treatment based on synergy between anti-angiogenic and immune cell therapies
Soto-Ortiz, L., & Finley, S. D. (2016) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2016.01.026 · Cited by 29
Lymphatic Endothelial Cell Progenitors in the Tumor Microenvironment
Ran, S., & Volk-Draper, L. D. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-37184-5_7 · Cited by 30
Thomas, A. A., Fisher, J. L., Hampton, T. H., Christensen, B. C., Tsongalis, G. J., Rahme, G. J., Whipple, C. A., Steel, S. E., Davis, M. C., Gaur, A. B., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1941-3 · Cited by 30
A vasculature-centric approach to developing novel treatment options for glioblastoma
Wirsching, H., Roth, P., & Weller, M. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1881062 · Cited by 28
The effect of anti-angiogenic drugs on regulatory T cells in the tumor microenvironment
Hu, C., & Jiang, X. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.01.051 · Cited by 27
VEGF: Potential therapy for renal regeneration
Chade, A. (2012) · F1000 Medicine Reports · doi:10.3410/m4-1 · Cited by 26
“AntiVEGF therapies are already part of the first line of treatment in colon cancer [13] and their use in other types of solid tumors is under extensive investigation [14,15].”
BackgroundVEGF and Pleiotrophin Modulate the Immune Profile of Breast Cancer
Lynn, K. D., Roland, C. L., & Brekken, R. A. (2010) · Cancers · doi:10.3390/cancers2020970 · Cited by 28
“A recent study from Duke evaluated the effect of bevacizumab therapy on immune cells in patients with a variety of cancers, including breast cancer [90].”
InfluentialChemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer
Martín-Romano, P., Ammari, S., El-Dakdoukti, Y., Baldini, C., Varga, A., Vuagnat, P., Angevin, E., Bahleda, R., Gazzah, A., Champiat, S., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.06.030 · Cited by 26
Liu, Z.-L., Liu, J., Staiculescu, D., & Chen, J. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211018026 · Cited by 27
Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?
Shurin, M. R., Gregory, M., Morris, J. C., & Malyguine, A. M. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.526105 · Cited by 27
“Moreover, anti-VEGF antibody treatment enhances allo-stimulatory capacity of DC and T cell proliferation against recall antigens [57].”
BackgroundGatson, N. T., Weathers, S.-P. S., & de Groot, J. (2015) · CNS Oncology · doi:10.2217/cns.15.38 · Cited by 26
RetractedGuardascione, M., & Toffoli, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176302 · Cited by 24
“Data from studies of peripheral blood of patients who underwent bevacizumab treatment showed that anti-VEGF treatment increased the number of DCs [69], underlying a VEGF capability to inhibit maturation and proliferation of DCs.”
BackgroundInfluentialMyeloid-derived suppressor cells in colorectal cancer: prognostic biomarkers and therapeutic targets
Al-Mterin, M. A., & Elkord, E. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00097 · Cited by 25
“Moreover, administration of anti-VEGF (bevacizumab) was related with a reduction in the concentration of immature progenitor cells and generated a moderate rise in DC population in the peripheral blood of CRC patients [83].”
BackgroundZhou, C., & Zhang, J. (2019) · Frontiers of Medicine · doi:10.1007/s11684-019-0685-9 · Cited by 24
First-line ICIs in renal cell carcinoma
Fiorentino, V., Tralongo, P., Larocca, L. M., Pizzimenti, C., Martini, M., & Pierconti, F. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2225386 · Cited by 23
“In fact, when VEGF is highly expressed, less differentiated antigenpresenting dendritic cells and more immunosuppressive myeloid cells are found in tumor tissue and peripheral blood, respectively.(28,29) Also, it has been proven that VEGF blockade increases the number of T-cells within a tumor; in fact, Wallin et al.”
BackgroundBencsiková, B., Budínská, E., Selingerová, I., Pilátová, K., Fědorová, L., Greplová, K., Nenutil, R., Valík, D., Obermannova, R. L., Sheard, M. A., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5909-5 · Cited by 22
Buttigliero, C., Allis, S., Tucci, M., Zichi, C., Leone, G., Stefano, R. F. D., Redda, M. G. R., Ricardi, U., Scagliotti, G. V., Maïo, M. D., et al. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.07.010 · Cited by 22
Perspectives on Reprograming Cancer-Associated Dendritic Cells for Anti-Tumor Therapies
Benencia, F., Muccioli, M., & Alnaeeli, M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00072 · Cited by 23
“Interestingly, tumor patients treated with antiVEGF antibody showed decreased levels of immunosuppressive DCs (61).”
BackgroundBuchroithner, J., Pichler, J., Marosi, C., Widhalm, G., Seiz‐Rosenhagen, M., Nowosielski, M., Oberndorfer, S., Ruckser, R., Rössler, K., Azizi, A. A., et al. (2013) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpxces13ea02 · Cited by 21
“VEGF has been shown to have an impact on dendritic cell differentiation and may inhibit the ability of mature dendritic cells to stimulate T cells, and inhibition of VEGF-signaling may have a direct effect on tumor cells by inducing cellular senescence [3, 4, 5, 6].”
BackgroundCell-mediated immune resistance in cancer
Wang, Y., Hays, E., Rama, M., & Bonavida, B. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.98 · Cited by 25
“VEGF was previously shown to block immature myeloid cell and DC maturation, reducing their antigen presentation capabilities and dampening the immune stimulatory phenotype([123]).”
BackgroundThe role of talactoferrin alfa in the treatment of non-small cell lung cancer
Kelly, R. J., & Giaccone, G. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.512914 · Cited by 20
“The immunologic response of patients to cancer is decreased by high levels of circulating VEGF [31] and it has been suggested that the addition of talactoferrin to a small molecule VEGF tyrosine kinase inhibitor may enhance efficacy [30].”
BackgroundSammarco, E., Manfredi, F., Nuzzo, A., Ferrari, M., Bonato, A., Salfi, A., Serafin, D., Zatteri, L., Antonuzzo, A., & Galli, L. (2023) · Cancers · doi:10.3390/cancers15123172 · Cited by 21
“In addition, these drugs may restore an immune-sensitive TME by reducing the levels of cells with immunosuppressive functions, such as MDSCs and regulatory T cells and promoting the differentiation of monocytes into mature dendritic cells [43].”
BackgroundAnti-angiogenesis immunotherapy
Schoenfeld, J. D., & Dranoff, G. (2011) · Human Vaccines · doi:10.4161/hv.7.9.16407 · Cited by 21
Ultrasound-based combination therapy: potential in urologic cancer
Finley, D. S., Pouliot, F., Shuch, B. M., Chin, A. I., Pantuck, A. J., deKernion, J. B., & Belldegrun, A. S. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.174 · Cited by 19
The Emerging Role of Immunotherapy in Gastric and Esophageal Adenocarcinoma
Bockorny, B., & Pectasides, E. (2016) · Future Oncology · doi:10.2217/fon-2016-0103 · Cited by 19
Stühler, V., Rausch, S., Maas, J. M., Stenzl, A., & Bedke, J. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1890713 · Cited by 18
On Deep Landscape Exploration of COVID-19 Patients Cells and Severity Markers
Vázquez-Jiménez, A., de León, U. A.-P., Matadamas-Guzman, M. L., Muciño-Olmos, E. A., Martínez-López, Y. E., Escobedo-Tapia, T., & Reséndis-Antonio, O. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.705646 · Cited by 19
Szala, S., Mitrus, I., & Sochanik, A. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0873-6 · Cited by 19
Ishikawa, M., Nakayama, K., Nakamura, K., Yamashita, H., Ishibashi, T., Minamoto, T., Iida, K., Razia, S., Ishikawa, N., Nakayama, S., et al. (2020) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-020-05589-0 · Cited by 22
Liang, J., Liu, X., Xie, Q., Chen, G., Li, X., Jia, Y., Yin, B., Qu, X., & Li, Y. (2016) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2016.04.09 · Cited by 19
Correale, P., Cusi, M. G., & Tagliaferri, P. (2010) · Immunotherapy · doi:10.2217/imt.10.92 · Cited by 18
Angiogenesis in biliary tract cancer: targeting and therapeutic potential
Rimini, M., & Gardini, A. C. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1881479 · Cited by 17
“These findings have been confirmed in clinical studies conducted in others oncologic settings, such as colon-rectal cancer patients and HCC [55], where it has been highlighted that VEGF inhibition by bevacizumab improved the antigen-presenting capacity of circulating dendritic cells [56], thus suggesting an additional…”
ResultChen, M., Xu, Y., Zhao, J., Liu, X., Liu, X., Zhang, D., Shi, Y., Zhang, L., Zhong, W., & Wang, M. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.12.003 · Cited by 17
Wang, K., Feng, J., Yu, H., Cheng, Y., Xiang, Y., Liu, Z., Qin, Y., Liu, E., Shan, Y., Chen, F., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02427-0 · Cited by 16
“31,32 Together, combination treatment with these agents addresses the limitations of TACE monotherapy, offering a comprehensive therapeutic strategy to intermediate HCC.”
Advances in Immunotherapy for Hepatocellular Carcinoma
Hagiwara, S., Nishida, N., & Kudo, M. (2023) · Cancers · doi:10.3390/cancers15072070 · Cited by 18
Matteucci, L., Bittoni, A., Gallo, G., Ridolfi, L., & Passardi, A. (2023) · Cancers · doi:10.3390/cancers15215189 · Cited by 19
Tumor hypoxia: Classification, detection, and its critical role in cancer progression
Zhao, Y., Zhong, B., Cao, J., Wang, Q., Liang, J., Lu, K., & Lu, S. (2025) · Biomolecules and Biomedicine · doi:10.17305/bb.2025.12318 · Cited by 17
Clay, T. M., Osada, T., Hartman, Z. C., Hobeika, A. C., Devi, G. R., Morse, M. A., & Lyerly, H. K. (2010) · Immunologic Research · doi:10.1007/s12026-010-8186-6 · Cited by 17
“Subsequently, we studied the effect of administration of the anti-VEGF antibody (bevacizumab) on DC maturation and function in vivo [59, 60].”
BackgroundSelf-citationModulation of Tumor Vasculature Network: Key Strategies
Taleb, M., Mohammadkhani, N., Bahreini, F., Ovais, M., & Nie, G. (2022) · Small Structures · doi:10.1002/sstr.202100164 · Cited by 16
Dendritic cells in the skin – potential use for melanoma treatment
Marsafy, S. E., Bagot, M., Bensussan, A., & Mauviel, A. (2009) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2008.00532.x · Cited by 18
“Furthermore, the negative association between elevated levels of VEGF and DC differentiation (Osada et al., 2008) might explain, in part, the impaired anticancer immunity in advanced malignancies.”
BackgroundZhang, H., Xia, W., Liang, C., Wang, X., Zhi, L., Guo, C., Niu, Z., & Zhu, W. (2020) · Molecular Immunology · doi:10.1016/j.molimm.2020.04.005 · Cited by 15
Immune checkpoint inhibition for the treatment of renal cell carcinoma
Stühler, V., Maas, J. M., Rausch, S., Stenzl, A., & Bedke, J. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1677601 · Cited by 17
Are antiangiogenics a good ‘partner’ for immunotherapy in ovarian cancer?
García-Martínez, E., Redondo, A., Piulats, J. M., Garzotto, A. A. R., & Casado, A. (2020) · Angiogenesis · doi:10.1007/s10456-020-09734-w · Cited by 17
Metadata
- Authors
- Osada, T., Chong, G., Tansik, R., Hong, T., Spector, N., Kumar, R., Hurwitz, H. I., Dev, I., Nixon, A. B., Lyerly, H. K., Clay, T., & Morse, M. A.
- Affiliations
- Duke Medical Center (US)
- GlaxoSmithKline (United Kingdom) (GB)
- Hartford Hospital (US)
- Corresponding author
- Morse, Michael A.
- ORCID
- Venue
- Cancer Immunology Immunotherapy
- Published
- 2008-01-10
- Volume
- 57
- Issue
- 8
- Pages
- 1115-1124
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC4110970
- OpenAlex
- W2067969350
- Cited by
- 311
- References
- 35
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 15 · 2023: 22 · 2022: 18 · 2021: 30 · 2020: 26 · 2019: 16 · 2018: 24 · 2017: 21 · 2016: 19 · 2015: 12 · 2014: 13 · 2013: 14 · 2012: 10
- FWCI
- 7.26
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Immunology Immunotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- GlaxoSmithKline
- National Cancer Institute (K24CA113755, P01CA078673, 5 P01 CA78673.)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- anti-VEGF therapy, bevacizumab, dendritic cells, immature myeloid cells, DC2, dendritic cell maturation, vascular endothelial growth factor, angiogenesis, plasminogen activator inhibitor-1, urokinase, D-dimer, antitumor immunity, lung cancer, breast cancer, colorectal cancer, T cell proliferation
- MeSH terms
- Bevacizumab, Antibodies, Monoclonal, Breast Neoplasms, Cell Differentiation, Cells, Cultured, Dendritic Cells, Fibrin Fibrinogen Degradation Products, Humans, Immunotherapy, Lung Neoplasms, Neovascularization, Pathologic, Pilot Projects, T-Lymphocytes, Urokinase-Type Plasminogen Activator, Colorectal Neoplasms, Plasminogen Activator Inhibitor 1, Angiogenesis Inhibitors, Myeloid Progenitor Cells, Vascular Endothelial Growth Factor A, Cell Proliferation, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.